Novo Nordisk A/S (NYSE:NVO) has moved one step closer to bringing its oral Wegovy treatment to China after the country’s drug regulator accepted the company’s marketing application.
The filing gives Novo an opportunity to expand its weight-management business in the world’s second-largest pharmaceutical market, where demand for GLP-1 therapies is expected to grow substantially. However, accepting an application is not the same as approving it, and Novo has declined to provide a potential regulatory timeline.
Bull Case
China presents a potentially significant long-term market for weight-management treatments. The country’s National Health Commission has said that more than 65% of the population could be overweight or obese by 2030, creating demand for additional treatment options alongside broader public-health measures. J.P. Morgan’s head of China healthcare research, Yang Huang, told Reuters that he estimates Chinese sales of GLP-1 weight-management therapies could reach 30 billion yuan, or approximately $4.46 billion, within the next five to seven years. That would represent a substantial increase from the current estimated market size of between 3 billion and 4 billion yuan.
Furthermore, an oral version of Wegovy could help Novo reach patients who are reluctant to use injectable medicines. Novo and Eli Lilly believe weight-loss pills may attract people who would otherwise avoid treatment because they do not want injections. Novo also brings experience from other markets, as the Wegovy pill has received regulatory approval in the United States and Britain, and the company launched it in the US earlier in 2026. Those approvals do not determine the outcome of the Chinese review, but they demonstrate that the product has already passed regulatory assessment in two major markets.
The application could also broaden Novo’s presence beyond once-weekly injections. Novo, Lilly, Pfizer and China-based Innovent Biologics are competing with injectable GLP-1 weight-management products in the country. Adding a pill would give Novo another formulation through which to address the market, and acceptance of the application confirms that the Chinese regulator will evaluate oral Wegovy for potential marketing authorization. It is an early regulatory milestone rather than a final decision, but it moves the treatment closer to possible commercial availability.
Bear Case
The most important limitation is that oral Wegovy has not been approved in China. Novo has not disclosed when a decision could arrive and told Reuters that it could not provide information about possible approval timelines because it respects the regulatory-review process. That uncertainty makes it difficult to estimate when the treatment might begin generating Chinese revenue. Regulators could approve the application, request additional information, or decline it, and the current information provides no basis for predicting the outcome.
Lilly also appears to have moved earlier. The company submitted its Chinese marketing application for once-daily orforglipron at the end of 2025. A Lilly executive told Reuters that the drug could launch in China as early as 2026, although that remains a company expectation rather than a confirmed launch date. The market is already competitive as well. Novo, Lilly, Pfizer, and Innovent are seeking share through their injectable GLP-1 products, meaning oral Wegovy would enter an established contest rather than an uncontested category.
The 30-billion-yuan market projection should also be treated cautiously. It is an analyst forecast for the entire Chinese GLP-1 weight-management market, and not an exact estimate of Wegovy’s future sales. Novo’s eventual share will depend on regulatory timing, patient demand, and its performance against other available treatments.
Conclusion
China’s acceptance of Novo’s application opens a potentially important route for expanding oral Wegovy. The country’s growing weight-management needs, the projected expansion of GLP-1 sales, and the pill’s appeal to injection-averse patients support the opportunity.
Nevertheless, the filing remains at the review stage, with no disclosed decision date. Oral Wegovy could strengthen Novo’s position in China, but its commercial contribution will depend on regulatory approval and how effectively the company competes in an increasingly crowded market.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center